Current and Emerging Biomarkers in Lung Cancer Therapy
- New and emerging predictive biomarkers for targeted therapies
- RET fusions
- METex14-skipping mutations
- NTRK fusions
- ROS1 rearrangements
- KRAS mutations
- HER2 mutations
- Predictive biomarkers for immune checkpoint inhibitor therapy
- Tumor mutational burden
Key Strategies for Biomarker Detection
- Best practices for sample collection
- Assays for the detection of gene fusions and mutations
- Laboratory developed
- Commercially available
- Comprehensive molecular profiling assays and methodologies
- Plasma cell–free DNA genomic testing
- PD-L1 testing by IHC
Precision Medicine in Lung Cancer: Clinical Pearls and Future Directions
Date / Time
Matthew Gubens, MD
University of California, San Francisco
San Francisco, California
Sanjay Mukhopadhyay, MD
Director, Pulmonary Pathology
Department of Pathology
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung cancer.
This program is intended for physicians, pathologists, and other healthcare providers who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Assess new and emerging predictive biomarkers to guide therapeutic decisions in patients with lung cancer
- Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
- Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
- Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0. Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning (Part II) and Self-Assessment Module (SAM) points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.